Structure Therapeutics to present promising data on ACCG-2671 for obesity and GLP-1 receptor agonists for Parkinson's at ADA 2025. Structure Therapeutics announced two late-breaking poster ...
SAN FRANCISCO, June 20, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results